Literature DB >> 18661410

Long-term efficacy and safety of quadruple therapy in childhood diffuse proliferative lupus nephritis.

Gülay Demircin1, Ayse Oner, Ozlem Erdoğan, Ali Delibaş, Sahika Baysun, Mehmet Bülbül, Kenan Bek, Ayşegül Oksal.   

Abstract

In this study, we evaluated the frequency, clinical presentation, treatment protocols, prognostic factors, and outcome in children with diffuse proliferative lupus nephritis (DPLN). Between June 1990 and December 2004, 46 patients were diagnosed to have systemic lupus erythematosus (SLE), and 26 of them (56.5%) were found to have DPLN. Renal manifestations were present in 25 patients, and the majority of them presented with severe renal findings, such as nephrotic syndrome and renal failure. All patients were given a quadruple therapy protocol including 6-12 monthly courses of methyl prednisolone pulse therapy combined with oral prednisolone, oral cyclophosphamide, azathioprine, and dipyridamole. Nineteen of these patients were regularly followed up with a mean follow-up period of 5.9 years. Complete remission was achieved in 15 of 19 patients, and chronic renal failure developed in four patients. Renal survival rate was calculated to be 78.9% at the end of 5, 10, and 14 years. Although nephrotic range proteinuria, hypoalbuminemia, renal failure, and activity index above 12/24 at presentation seemed to be associated with poor prognosis, no significant difference could be found. Hypertension and chronicity index greater than 6/12 were found to be bad prognostic predictors. We concluded that satisfactory results were achieved with our quadruple therapy protocol; thus, more aggressive and expensive therapies can be avoided and preserved for more serious and persistent diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18661410     DOI: 10.1080/08860220802132171

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  6 in total

1.  An unusual case of ANA negative systemic lupus erythematosus presented with vasculitis, long-standing serositis and full-house nephropathy.

Authors:  Aysun Caltik; Gülay Demircin; Mehmet Bülbül; Ozlem Erdogan; Sare G Akyüz; Nilüfer Arda
Journal:  Rheumatol Int       Date:  2010-06-08       Impact factor: 2.631

2.  Calcium signaling in systemic lupus erythematosus T cells: a treatment target.

Authors:  Vasileios C Kyttaris; Zheng Zhang; Ourania Kampagianni; George C Tsokos
Journal:  Arthritis Rheum       Date:  2011-07

3.  Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis.

Authors:  Hermine I Brunner; Michael R Bennett; Rina Mina; Michiko Suzuki; Michelle Petri; Adnan N Kiani; Joshua Pendl; David Witte; Jun Ying; Brad H Rovin; Prasad Devarajan
Journal:  Arthritis Rheum       Date:  2012-08

Review 4.  Biomarkers and updates on pediatrics lupus nephritis.

Authors:  Michael Bennett; Hermine I Brunner
Journal:  Rheum Dis Clin North Am       Date:  2013-07-16       Impact factor: 2.670

Review 5.  Cyclophosphamide and lupus nephritis: when, how, for how long?

Authors:  Stella Ntali; George Bertsias; Dimitrios T Boumpas
Journal:  Clin Rev Allergy Immunol       Date:  2011-06       Impact factor: 8.667

6.  Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis.

Authors:  Lindsey E Romick-Rosendale; Hermine I Brunner; Michael R Bennett; Rina Mina; Shannen Nelson; Michelle Petri; Adnan Kiani; Prasad Devarajan; Michael A Kennedy
Journal:  Arthritis Res Ther       Date:  2011-12-07       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.